Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.
KOLs interviewed by GlobalData consistently recognized tirzepatide's cardiometabolic value as extending well beyond weight loss alone.
The joint effort began with AI-assisted IND submission preparation and has since expanded to HAQ and RTQ processes.
The approval is based on data from the global Phase III SURPASS ET trial, demonstrating durable ELN responses and control.
Paxalisib is being studied in various cancers and has received several regulatory designations from the FDA.
Aitia will use its platform to analyse clinical and omics data and construct digital models for predictions.
